Email: info@allergy.org.au
Website: https://allergy.org.au

©2023 Australasian Society of Clinical Immunology and Allergy (ASCIA)
ABN 45 615 521 452

 

Immunodeficiency

Primary immunodeficiencies (PIDs), also known as inborn errors of immunity (IEI) include more than 400 potentially serious disorders that can lead to frequent or severe infections, swellings (hereditary angioedema [HAE]) and autoimmune problems. PID/IEI discorders can be caused by defects in genes that control the immune system, and may be inherited. 

Note: ASCIA Immunoglobulin Replacement Therapy (IRT) and Subcutaneous Immunoglobulin (SCIg) information is mostly not specific for PID, and can be used by other medical specialties. 

Information for Health Professionals

ASCIA Immunodeficiency e-training courses - PID, IRT*, HAE* *New 2022

Primary Immunodeficiencies (PIDs)

ASCIA Immunodeficiency Strategy for Australia and New Zealand Launched May 2022

ASCIA Guidelines for Diagnosis and Management of Severe Combined Immunodeficiency (SCID) in Australia and New Zealand: A TAPID Consensus Guideline

ASCIA PID Clinical Update 

References - Immunodeficiency

ASCIA ID Register How to access information (available to ASCIA members only)

Immunoglobulin Replacement Therapy (IRT) 

ASCIA Position Statement - IRT in PID Updated August 2022

ASCIA Guidelines - Standardised IVIg Infusion Rates for IRT Updated April 2023 

ASCIA Transfer Care Plan for patients on IRT

Subcutaneous Immunoglobulin (SCIg)

ASCIA SCIg Checklists - Nurse Competency and Patient Training 

ASCIA SCIg Treatment Plan

ASCIA Travel Plan for patients on SCIg

ASCIA SCIg Position Statement  

ASCIA Guide – Setting up a SCIg program in a hospital

Hereditary Angioedema (HAE)

ASCIA HAE Position Paper and Management Plan Updated October 2022

References - HAE

ASCIA Webinar - HAE

Further Information
Patient and carer support organisations 
 
ASCIA information for patients and carers

ASCIA information for health professionals 

Webpage updated April 2023